Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Vogwel M
Vogwel M (Voglibose & Metformin Tablets) is a powerful oral antidiabetic combination designed for patients with type 2 diabetes mellitus. It helps in achieving better glycemic control by addressing both fasting and postprandial blood sugar levels. This combination therapy is ideal for individuals who struggle with post-meal glucose spikes and require additional support beyond lifestyle modifications and monotherapy.
Uses of Vogwel M
Management of type 2 diabetes mellitus
Reduces postprandial hyperglycemia
Enhances insulin sensitivity and glucose utilization
Prevents complications associated with diabetes
Benefits of Vogwel M
Dual mechanism for superior glycemic control
Reduces carbohydrate absorption, preventing sugar spikes
Improves insulin function and lowers fasting glucose levels
Helps in weight management due to minimal risk of hypoglycemia
Prevents microvascular and macrovascular complications
Mechanism of Action of Vogwel M
Voglibose, an α-glucosidase inhibitor, delays intestinal carbohydrate breakdown and absorption, reducing post-meal glucose levels. Metformin, a biguanide, works by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing glucose uptake in peripheral tissues. This synergistic action ensures better glycemic control throughout the day.